Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tax-specific redirected T-cell therapy (TaxCTL-2402) in adult T-cell leukemia/lymphoma
jRCT2033250739Phase 2Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jan 2026
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TaxCTL-2402 in adult T-cell leukemia-lymphoma (ATLL), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Safety (Phase I) and Objective response rate (Phase II). Started Jan 2026; status: recruiting.
02
Drugs
TaxCTL-2402
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on jRCT2033250739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033250739.